Healthy volunteers
Conditions
Interventions
Subjects receive a single oral dose of 180-mg ONO-1110.
Sponsors
Namba Yoshinobu
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Healthy Japanese adult males 2) The subject is aged 18 to 45 years, inclusive, at the time of signing the informed consent form. 3) The subject has a BMI of 18.5 kg/m2 or more and less than 25.0 kg/m2 (rounded down to 2 decimal places) at screening.
Exclusion criteria
Exclusion criteria: 1) An individual who is receiving treatment for or has a history of a respiratory, cardiovascular, psychiatric, neurological, gastrointestinal, immunological, hepatic, renal, hematopoietic, endocrine, or other disease 2) Subjects with current or perious history of severe allergy to drugs or food 3) The subject who is judged by the investigator or subinvestigator to be inappropriate as a subject of this study based on the results of screening tests
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma ONO-1110 concentrations and pharmacokinetic parameters | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events that occurred after administration of investigational product until the end of final examination | — |
Contacts
Public ContactCenter Medical
Ono Pharmaceutical Co.,LTD
Outcome results
None listed